Production (Stage)
Akero Therapeutics, Inc.
AKRO
$46.36
-$2.61-5.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.00% | 3.69% | -29.86% | -4.95% | 3.34% |
| Total Depreciation and Amortization | -- | 1,400.00% | 0.00% | 0.00% | -50.00% |
| Total Amortization of Deferred Charges | 2.30% | 6.10% | 4.46% | 40.18% | -6.67% |
| Total Other Non-Cash Items | 56.97% | 5.46% | -25.48% | 4.86% | 99.92% |
| Change in Net Operating Assets | -159.61% | 23.00% | 73.79% | -152.65% | 232.87% |
| Cash from Operations | -0.86% | 4.73% | -22.58% | -63.50% | 27.74% |
| Capital Expenditure | -- | -- | 100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3,257.30% | -79.10% | 128.67% | -540.62% | 352.44% |
| Cash from Investing | -3,257.30% | -79.10% | 128.55% | -542.35% | 352.44% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 421.06% | 2,327.98% | 857.49% | -99.91% | 66,919.14% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,886.21% | 54.69% | 86.58% | -74.09% | -783.87% |
| Cash from Financing | 420.50% | 2,377.70% | 2,144.67% | -100.04% | 72,995.22% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -738.38% | 323.35% | 101.82% | -180.46% | 1,202.60% |